This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-21 and is reviewed periodically as new material appears.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
=== Intravenous injection === Progesterone has a very short elimination half-life of about 3 to 90 minutes when given by intravenous injection. An aqueous solution of progesterone for use by intravenous injection was once marketed by Schering AG under the brand name Primolut Intravenous.
=== Age-related differences === While the amino acid scores for PDCAAS and DIAAS are based on toddler requirements (1–3 year olds), the essential amino acid requirements differ for adults and infants. The most demanding essential amino acid requirements are for infants; when children become adults, they need lower proportions of essential amino acids. This also means that many of the vegan protein sources that are limited in one or more essential amino acids, are actually less deficient in essential amino acids for adults, perhaps not deficient at all. Old age and pregnancy also change amino acid requirements, because of the necessity of supporting a fetus or slowing the loss of muscle due to age. The essential amino acid requirements for infants are based on the essential amino acid proportions in human breast milk.
=== Diplomatic means === A key element of US political, military and energy economic planning occurred in 1984. The Iran–Iraq war had been going on for five years and both had sustained casualties into the hundreds of thousands. Within President Ronald Reagan's National Security Council concern was growing war could spread beyond the two belligerents. A National Security Planning Group meeting was formed, chaired by then vice president George H. W. Bush, to review US options. It was determined that the conflict would likely spread into Saudi Arabia and other Gulf states, but the US had little capability to defend the region. A prolonged war in the region would induce much higher oil prices and threaten the recovery of the world economy, which was just beginning to gain momentum. In May 1984, President Reagan was briefed on the project conclusions by William Flynn Martin who had served as the head of the NSC staff that organized the study. The conclusions were: first, oil stocks needed to be increased among members of the International Energy Agency and, if necessary, released early if the oil market was disrupted; second, the US needed to strengthen the security of friendly Arab states in the region; and third, an embargo should be placed on sales of military equipment to Iran and Iraq. The plan was approved by Reagan and affirmed by the G7 leaders headed by the UK's prime minister, Margaret Thatcher, in the 10th G7 summit, held in London in June. The plan was implemented and became the basis for US preparedness to respond to the Iraqi occupation of Kuwait in 1991.
Unlabeled antibody is incubated in the presence of its antigen (sample) A sufficient incubation period is provided to allow the antibodies to bind to the antigens. The sample is then passed through the Scavenger container. This can be a test tube or a specifically designed flow through channel. The surface of the Scavenger container or channel has "Scavenger Antigens" bound to it. These can be identical or sufficiently similar to the primary antigens that the free antibodies will bind. The Scavenger container must have sufficient surface area and sufficient time to allow the Scavenger Antigens to bind to all the excess Antibodies introduced into the sample. The sample, that now contains the tagged and bound antibodies, is passed through a detector. This device can be a flow cytometer or other device that illuminates the tags and registers the response. This test allows multiple antigens to be tagged and counted at the same time. This allows specific strains of bacteria to be identified by two (or more) different color tags. If both tags are present on a cell, then the cell is that specific strain. If only one is present, it is not. This test is done, generally, one test at a time and cannot be done with the microtiter plate. The equipment needed is usually less complicated and can be used in the field.
Porous glass is glass that includes pores, usually in the nanometre- or micrometre-range, commonly prepared by one of the following processes: through metastable phase separation in borosilicate glasses (such as in their system SiO2-B2O3-Na2O), followed by liquid extraction of one of the formed phases; through the sol-gel process; or simply by sintering glass powder. The specific properties and commercial availability of porous glass make it one of the most extensively researched and characterized amorphous solids. Due to the possibility of modeling the microstructure, porous glasses have a high potential as a model system. They show a high chemical, thermal and mechanical resistance, which results from a rigid and incompressible silica network. They can be produced in high quality and with pore sizes ranging from 1 nm up to any desired value. An easy functionalization of the inner surface opens a wide field of applications for porous glasses. A further special advantage of porous glasses compared to other porous materials, is that they can be made not only as powder or granulate, but also as larger pieces in almost any user defined shape and texture.
Sources: en.wikipedia.org
Janis, made by Video Arts Television 4 November A Brush with the Greens, about environmental consumer products; the consumer products company Creightons of Billingshurst was looking at developing new products and had an environmental audit by John Elkington; deep ecology; the PA Consulting Group; the Predicasts database; the CEGB wind energy demonstration site in west Wales at Carmarthen Bay Power Station; a million tonnes of plastic packaging waste was caused in the UK each year; separating plastic waste would allow much more recycling of household plastics; the Greater Manchester Waste Disposal Authority; the Purfleet Board plant in Essex, which itself was powered by landfill gas through a Ruston Gas Turbines TB5000 CHP plant, which closed in 2004; a focus group (four women) takes place, where the product designers sit behind a two-way mirror, with new toothpaste designs placed on a mood board. Narrated by wine critic Jancis Robinson, produced by Mike Cockburn, directed by David Sharp, made by London Scientific Films 11 November Patently Obvious?, about acquiring patents in the UK; scenes from the 1951 The Man in the White Suit and The Dam Busters; Barry Fox of New Scientist, and the invention of FM by Edwin Howard Armstrong; Jeremy Phillips of Queen Mary and Westfield College; computer software cannot be patented; Peter Chilvers, who disputed an American patent; the British Technology Group; Richard Taylor and Paul Kellar of Quantel; in the European Patent Organisation, the UK had 6% of patents but the US and Germany had 25% each; Robert Donat in 1951 The Magic Box.
=== Patents === Ayyappanpillai Ajayaghosh; Chakkooth Vijayakumar; Vakayil K. Praveen (10 September 2013). "White light emitting organogel and process thereof". Patent No. 8529790. {{cite journal}}: Cite journal requires |journal= (help) Ayyappanpillai Ajayaghosh; Sivaramapanicker Sreejith (1 January 2013). "Pyrrole end-capped bipyridine assay powder for selective detection of zinc ions and a process for the preparation thereof". Patent No. 8344150. {{cite journal}}: Cite journal requires |journal= (help) Ayyappanpillai Ajayaghosh; Sampath Srinivasan; Vakayil Praveen (4 December 2012). "Nanocomposite material useful for the preparation superhydrophobic coating and a process for the preparation thereof". Patent No. 8323732. {{cite journal}}: Cite journal requires |journal= (help)
== History == Scurvy was known to Hippocrates, described in book two of his Prorrheticorum and in his Liber de internis affectionibus, and cited by James Lind. Symptoms of scurvy were also described by Pliny the Elder: (i) Pliny. "49". Naturalis historiae. Vol. 3.; and (ii) Strabo, in Geographicorum, book 16, cited in the 1881 International Encyclopedia of Surgery.
== Prognosis == In open-angle glaucoma, the typical progression from normal vision to complete blindness takes about 25 years to 70 years without treatment, depending on the method of estimation used.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.